Back to Search
Start Over
The impact of a pathologist's personality on the interobserver variability and diagnostic accuracy of predictive PD-L1 immunohistochemistry in lung cancer
- Source :
- Butter, R, Hondelink, L M, van Elswijk, L, Blaauwgeers, J L G, Bloemena, E, Britstra, R, Bulkmans, N, van Gulik, A L, Monkhorst, K, de Rooij, M J, Slavujevic-Letic, I, Smit, V T H B M, Speel, E-J M, Thunnissen, E, von der Thusen, J H, Timens, W, van de Vijver, M J, Yick, D C Y, Zwinderman, A H, Cohen, D, 't Hart, N A & Radonic, T 2022, ' The impact of a pathologist's personality on the interobserver variability and diagnostic accuracy of predictive PD-L1 immunohistochemistry in lung cancer ', Lung Cancer, vol. 166, pp. 143-149 . https://doi.org/10.1016/j.lungcan.2022.03.002, Lung Cancer, 166, 143-149. ELSEVIER IRELAND LTD, Lung Cancer, 166, 143-149. Elsevier Ireland Ltd, Lung cancer (Amsterdam, Netherlands), 166, 143-149. Elsevier Ireland Ltd
- Publication Year :
- 2022
-
Abstract
- OBJECTIVES: Programmed death-ligand 1 (PD-L1) is the only approved predictive biomarker for immunotherapy in non-small cell lung cancer (NSCLC). However, predictive PD-L1 immunohistochemistry is subject to interobserver variability. We hypothesized that a pathologist's personality influences the interobserver variability and diagnostic accuracy of PD-L1 immunoscoring.MATERIALS AND METHODS: Seventeen pathologists performed PD-L1 immunoscoring on 50 resected NSCLC tumors in three categories (RESULTS: The overall agreement among pathologists for a series of 47 tumors was substantial (kappa = 0.63). Of these, 23/47 (49%) tumors were entirely negative or largely positive, resulting in a kappa value of 0.93. The remaining 24/47 (51%) tumors had a PD-L1 score around the cutoff value, generating a kappa value of 0.32. Pathologists with high scores for conscientiousness (careful, diligent) had the least interobserver variability (r = 0.6, p = 0.009). Also, they showed a trend towards higher sensitivity (74% vs. 68%, p = 0.4), specificity (86% vs. 82%, p = 0.3) and percent agreement (83% vs. 79%, p = 0.3), although not significant. In contrast, pathologists with high scores for neuroticism (sensitive, anxious) had significantly lower specificity (80% vs. 87%, p = 0.03) and percent agreement (78% vs. 85%, p = 0.03). Also, a trend towards high interobserver variability (r = -0.3, p = 0.2) and lower sensitivity (68% vs. 74%, p = 0.3) was observed, although not significant. Pathologists with relatively high scores for conscientiousness scored fewer tumors PD-L1 positive at the ≥ 1% cut-off (r = -0.5, p = 0.03). In contrast, pathologists with relatively high scores for neuroticism score more tumors PD-L1 positive at ≥ 1% (r = 0.6, p = 0.017) and ≥ 50% cut-offs (r = 0.6, p = 0.009).CONCLUSIONS: This study is the first to demonstrate the impact of a pathologist's personality on the interobserver variability and diagnostic accuracy of immunostaining, in the context of PD-L1 in NSCLC. Larger studies are needed for validation of these findings.
- Subjects :
- Observer Variation
Pulmonary and Respiratory Medicine
EXPRESSION
Cancer Research
Lung Neoplasms
Non-small cell lung cancer (NSCLC)
DECISION-MAKING
programmed death-ligand 1 (PD-L1)
Immunohistochemistry
B7-H1 Antigen
Pathologists
Oncology
SDG 3 - Good Health and Well-being
Carcinoma, Non-Small-Cell Lung
Biomarkers, Tumor
Humans
CELL
Interobserver variability
PEMBROLIZUMAB
TRAITS
Personality
Diagnostic reliability
Subjects
Details
- Language :
- English
- ISSN :
- 01695002
- Database :
- OpenAIRE
- Journal :
- Butter, R, Hondelink, L M, van Elswijk, L, Blaauwgeers, J L G, Bloemena, E, Britstra, R, Bulkmans, N, van Gulik, A L, Monkhorst, K, de Rooij, M J, Slavujevic-Letic, I, Smit, V T H B M, Speel, E-J M, Thunnissen, E, von der Thusen, J H, Timens, W, van de Vijver, M J, Yick, D C Y, Zwinderman, A H, Cohen, D, 't Hart, N A & Radonic, T 2022, ' The impact of a pathologist's personality on the interobserver variability and diagnostic accuracy of predictive PD-L1 immunohistochemistry in lung cancer ', Lung Cancer, vol. 166, pp. 143-149 . https://doi.org/10.1016/j.lungcan.2022.03.002, Lung Cancer, 166, 143-149. ELSEVIER IRELAND LTD, Lung Cancer, 166, 143-149. Elsevier Ireland Ltd, Lung cancer (Amsterdam, Netherlands), 166, 143-149. Elsevier Ireland Ltd
- Accession number :
- edsair.doi.dedup.....7e91c4dfdf95aaf2d5c8858a92d701a4
- Full Text :
- https://doi.org/10.1016/j.lungcan.2022.03.002